The present disclosure relates oligosaccharide preparations suitable for use in nutritional compositions such as animal feed and methods of manufacturing the described oligosaccharide preparations. The present disclosure further relates to nutritional compositions that comprise the oligosaccharide preparations. The disclosed oligosaccharide preparations can be advantageous as an animal feed due to, at least in part, their prebiotic utility and the presence of anhydro-subunit containing oligosaccharides, which can be used to detect and/or determine the presence and content of the disclosed oligosaccharide preparations in the nutritional composition.

A food grade water-soluble arabinoxylan product containing arabinoxylan oligosaccharides and retaining a high amount of bound ferulic acid and other phenolic substances is isolated from corn fiber using an aqueous extraction wherein the pH of the aqueous medium employed for the extraction is adjusted to a selected value after mixing with the corn fiber and prior to the initiation of extraction.

The present application relates to the technical field of further processing of dairy products, and in particular to a preparation method of milk oligosaccharides, and milk oligosaccharide powder and food prepared thereby. The preparation method comprises the steps of: performing ultrafiltration of whey liquid for at least three times, subjecting the ultrafiltration permeate to nanofiltration concentration for several times, then subjecting the nanofiltration retentate to chromatographic separation and purification, collecting chromatographic collection liquid containing sialyllactose while removing the fraction containing lactose, subjecting the collection to desalination and drying to obtain oligosaccharide powder. The milk oligosaccharides prepared by the present method and the food product containing the same comprise basically bovine milk oligosaccharides, which are light yellow or white in color, light in flavor, uniform in size, and have good thermal stability and solubility. The milk oligosaccharides mainly comprise 3′-sialyllactose and 6′-sialyllactose.

The present disclosure relates to novel modular methods for generating a diversity of N-glycans of high mannose, hybrid and complex types. The present disclosure also relates to exemplary arrays of the synthesized N-glycans spotted onto aluminium oxide coated slides. These arrays can be used to detect and analyze binding interactions between the synthesized N-glycans and glycan binding molecules, such as HIV-1 neutralizing antibodies. The present disclosure also relates to methods for identifying agents that bind to various types of molecules on the arrays and to defining the structural elements of the molecules on the arrays that bind to those agents. The arrays and methods provided herein may be used for general epitope identification, drug discovery and as analytical tools. The present disclosure also provides useful glycans and epitope determinants that are useful in detecting, diagnosing, recurrence monitoring and preventing pathological diseases such as HIV.

A purification method for the capsular polysaccharide of type II GBS in which the capsular polysaccharide is filtered using a membrane with a cut-off of less than 30 kDa.

An exopolysaccharide of a lactic acid bacterium derived from a fig and belonging to Lactobacillus paracasei includes a neutral polysaccharide having a structure in which N-acetylglucosamines are linked with each other via α-1,6 bond, has a hyaluronidase inhibitory, and is therefore useful in a food and drink, a medicine, a feed, a cosmetic and the like exerting an antiallergy effect.

Capsular saccharides derived from serogroups W135 and Y of Neisseria meningitidis have altered levels of O-acetylation at the 7 and 9 positions of their sialic acid residues, and can be used to make immunogenic compositions. Relative to unmodified native saccharides, derivatives of the invention are preferentially selected during conjugation to carrier proteins, and conjugates of the derivatives show improved immunogenicity compared to native polysaccharides.

The present invention relates to synthetic saccharides of general formula (I) that are related to Streptococcus pneumoniae serotype 4 capsular polysaccharide and conjugates thereof. Said conjugate and a pharmaceutical composition containing said conjugate are useful for prevention and/or treatment of diseases associated with Streptococcus pneumoniae, and more specifically of diseases associated with Streptococcus pneumoniae serotype 4. Furthermore, the synthetic saccharides of general formula (I) are useful as marker in immunological assays for detection of antibodies against Streptococcus pneumoniae bacteria.

In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.

Modified capsular saccharides comprising a blocking group at a hydroxyl group position on at least one of the monosaccharide units of the corresponding native capsular saccharide, wherein the blocking group is of the formula (Ia) or (Ib): —OX—Y (Ia) or —O—R.sup.1 (Ib) wherein X is C(O), S(O) or SO.sub.2; Y is NR.sup.1R.sup.2 or R.sup.3; R.sup.1 is C.sub.1-6 alkyl substituted with 1, 2 or 3 groups independently selected from hydroxyl, sulphydryl and amine; R.sup.2 is H or C.sub.1-6 alkyl; and R.sup.3 is C.sub.1-6 alkyl; processes for modifying a capsular saccharide with the blocking groups; saccharide-protein conjugates comprising the modified capsular saccharide; processes for making the saccharide-protein conjugates, pharmaceutical compositions comprising the modified capsular saccharides and/or saccharide-protein conjugates; and methods and uses of the same.